Noticias de NVO_US
Noticias del mercado
Últimas noticias sobre NVO_US — 895 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Barclays raises its price target for Novo Nordisk to 310 Danish kroner (300), reiterates equal weight - BN
Las ventas de Mounjaro, el medicamento para la diabetes de Eli Lilly, aumentaron un 91 por ciento en el segundo trimestre del año a 9.940 millones de dólares, muy por encima de las expectativas de los analistas.
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk wins Dutch court injunction against semaglutide compounder
Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom
Una decepción en la investigación y un fracaso en las ventas de píldoras Wegovy perjudicaron a Novo, mientras que la franquicia de inyectables de Lilly superó una vez más las expectativas de los analistas.
Eli Lilly vs. Novo Nordisk: diverging momentum and what it means for the pair trade
Novo Nordisk Underwhelms Investors With Soft Wegovy Pill Sales
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
Earnings call transcript: Novo Nordisk beats Q2 2026 estimates, shares rise premarket
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
Q2 2026 Novo Nordisk A/S Earnings Call Transcript
Novo Nordisk is evaluating several acquisition candidates and will step up the pace of research: CEO
Novo Nordisk Shares Slide as Wegovy Sales Miss Overshadow Strong First-half Results, Upgraded Outlook
Intron Health: Concerns about the obesity market have been confirmed for Novo Nordisk - BN
Novo Nordisk shares fall despite a hike to some full-year targets
???? Money Quote: Novo Nordisk CEO
Why is Novo Nordisk stock sliding today? By Investing.com
Analysts: Messy report from Novo Nordisk, Cagrisema and Wegovy dampen enthusiasm
Página 16 de 45